• 1
    Expert Panel Report 3 (EPR3). Guidelines for the diagnosis and management of asthma. U. S. Department of Health and Human Services, Bethesda, MD: National Heart, Lung and Blood Institute, 2007.
  • 2
    Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007; 16:227.
  • 3
    Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007; 30:4526.
  • 4
    Krishnan K, Diette GB, Rand CS et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006; 174:6338.
  • 5
    Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011; 128:116574.
  • 6
    Lasserson TJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2011; (12):CD004106.
  • 7
    Bousquet J, Cabrera P, Berkman N et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:3028.
  • 8
    Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:40513.
  • 9
    Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the SevereAsthma Research Program. Am J Respir Crit Care Med 2010; 181:31523.
  • 10
    Kupczyk M, Brinke AT, Sterk PJ et al. Frequent exacerbators' a distinct phenotype of severe asthma. Clin Exp Allergy 2014; 44:21221.
  • 11
    Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:112838.
  • 12
    Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:171521.
  • 13
    Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:245566.
  • 14
    Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:6519.